Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
301060 Shanghai Labway Clinical Laboratory
22.530
+0.120+0.54%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Per Share Indicator
Net Asset Per Share
33.53% 5.1291 25.26% 4.6928 -- 4.3498 12.67% 3.9073
Basic Earning Per Share
199.84% 1.5088 285.86% 1.075 192.47% 0.4425 84.64% 0.5783
Diluted  Earning Per Share
199.84% 1.5088 285.86% 1.075 192.47% 0.4425 84.64% 0.5783
Earning Per Share
240.74% 1.5088 285.86% 1.075 192.47% 0.4425 62.48% 0.5089
Diluted Earning Per Share(TTM)
223.67% 1.575 191.80% 1.3388 68.69% 0.8183 62.48% 0.5089
Capital Surplus Funds Per Share
0.94% 1.3932 6.14% 1.3907 -- 1.3802 5.33% 1.3802
Undivided Profit Per Share
87.91% 2.6415 60.75% 2.2076 -- 1.8752 30.87% 1.4326
Operating Cash Flow Per Share
-366.08% -0.6115 -2,113.03% -0.6794 -899.74% -0.3799 17.17% 0.5581
Enterprise FCF Per Share
85.70% -0.0756 122.71% 0.1417 -114.85% -0.2946 -164.53% -0.4651
Shareholder FCF Per Share
148.84% 0.2558 167.19% 0.4188 -114.85% -0.2946 -163.84% -0.4601
EBIT Per Share
225.63% 2.2104 273.67% 1.5713 214.99% 0.6914 74.11% 0.7955
Profitability
ROE Weighted
147.89% 33.540% 220.47% 24.740% 151.05% 10.720% 62.87% 15.000%
ROE
155.17% 29.418% 208.08% 22.907% -- 10.173% 44.24% 13.026%
ROA
98.97% 25.924% 163.21% 20.225% 142.43% 10.098% 56.12% 14.628%
ROIC
134.47% 36.565% 200.61% 27.622% 142.39% 13.060% 65.67% 17.969%
Net Profit Ratio
33.49% 23.576% 62.00% 25.560% 55.09% 27.928% 35.45% 14.711%
Gross Income Ratio
11.30% 43.763% 22.74% 46.773% -- 47.959% 18.40% 38.232%
EBIT To Total Operating Revenue
33.51% 28.477% 58.94% 30.541% 54.14% 33.458% 37.74% 17.916%
Period Costs Rate
-21.34% 14.018% -19.15% 15.253% -14.40% 14.116% 13.66% 20.221%
Operating Expense Rate
-27.51% 4.392% -32.22% 4.682% -- 5.022% 10.00% 7.056%
Admini Expense Rate
-20.14% 7.904% -9.85% 8.958% -- 7.552% 12.56% 10.888%
Financial Expense Rate
172.17% 0.168% 78.80% 0.074% -- 0.033% 204.23% 0.059%
Recurrent Net Profit
273.32% 606.52M 403.69% 428.34M 263.68% 173.78M 72.39% 181.97M
Operating Profit Ratio
35.15% 28.716% 59.69% 30.771% 55.08% 33.796% 24.43% 17.935%
EBIT
225.63% 885.31M 324.64% 629.34M 257.96% 276.93M 97.83% 318.61M
Solvency
Current Ratio
-53.34% 2.467 -49.16% 2.66 -- 3.8202 -25.55% 4.2788
Quick Ratio
-53.40% 2.2695 -47.63% 2.4896 -- 3.4599 -22.30% 3.9411
Debt Equity Ratio
151.17% 57.094% 120.55% 51.630% 44.12% 32.106% 58.05% 28.398%
Interest Cover(T)
-50.96% 169.2948 -41.80% 626.645 -- 1K -- 553.6766
Shareholders Equity Without Minority Interests To Total Liabilities
-61.96% 159.269% -56.66% 177.892% -- 289.905% -38.38% 336.060%
Shareholders Equity Without Minority Interests To Interest Bear Debt
-80.55% 1.74K% -81.40% 1.59K% -- 10.79K% -- 9.99K%
Long Debt To Working Capital
-18.06% 0.0297 -29.36% 0.0329 -- 0.0308 557.71% 0.0389
Growth Ability
Sustainable Grow Rate
154.31% 46.834% 238.05% 33.657% 181.31% 14.771% -22.85% 8.787%
Operating Capacity
Operating Cycle(D/T)
-14.25% 166.4733 -23.30% 149.0382 -- 146.5016 -14.07% 179.5733
Inventory Turnover Days(D/T)
-39.32% 29.6126 -51.05% 25.4499 -- 35.3801 -31.82% 46.96
Accounts Receivable Turnover Days(D/T)
-5.84% 136.8607 -13.16% 123.5883 -- 111.1216 -5.34% 132.6133
Inventory turnover Rate(T)
64.80% 9.1177 104.27% 7.0727 -- 2.5438 46.68% 7.6661
Accounts Receivable Turnover Rate(T)
6.20% 1.9728 15.15% 1.4564 17.22% 0.8099 5.65% 2.7147
Current Assets Turnover Rate(T)
48.54% 1.291 60.24% 0.9299 -- 0.4267 15.32% 1.1781
Total Assets Turnover Rate(T)
52.00% 1.0996 66.00% 0.7913 59.79% 0.3616 13.09% 0.9756
Fixed Assets Turnover Rate(T)
-- -- 30.72% 8.4875 -- -- 29.03% 12.7578
Equity Turnover Rate(T)
86.05% 1.718 97.21% 1.1965 -- 0.5006 23.83% 1.2761
Cash Position
Free Cash Flow
85.69% -30.3M 125.80% 56.74M -116.87% -117.98M -173.33% -186.27M
Net Profit Cash Cover
-43.12% -33.418% -480.62% -51.665% -215.56% -65.819% -31.56% 85.434%
Operating Revenue Cash Cover
-34.05% 51.364% -48.50% 41.471% -- 47.871% -23.96% 75.972%
Operating Cash In To Assets
-190.42% -8.663% -1,461.27% -10.449% -682.02% -6.647% 4.84% 12.262%
Dividend Ability
Dividend Per Share
-- -- -- -- -- -- -- 0.3
Dividend Cover(T)
-- -- -- -- -- -- -- 1.6965
Cash Dividend Cover(T)
-- -- -- -- -- -- -- 1.8602
Dividend Paid Ratio
-- -- -- -- -- -- -- 58.946%
Retained Earning Ratio
0.00% 100.000% 0.00% 100.000% 0.00% 100.000% -58.95% 41.054%
Capital Structure
Debt Assets Ratio
96.23% 36.344% 79.50% 34.050% 33.40% 24.303% 45.21% 22.117%
Current Assets To Total Assets
1.38% 85.913% 3.58% 85.885% -- 85.432% -1.43% 83.927%
Non Current Assets To Total Assets
-7.65% 14.087% -17.39% 14.115% -- 14.568% 8.19% 16.073%
Fix Assets Ratio
-- -- 10.38% 7.824% -- -- -3.89% 7.666%
Interest Bearing Debt To Total Capital
371.89% 4.966% 391.30% 5.446% -95.31% 0.855% -- 0.947%
Yield Quality
Invest Revenue From Associates To Total Profit
-- -0.057% -- -- -- -- -- --
Net Income From Value Changes To Total Profit
-79.38% 0.428% -81.25% 0.686% -- 1.265% -29.96% 3.198%
Recurrent Net Profit To Net Profit
14.65% 82.754% 16.37% 81.325% 0.97% 75.179% -11.38% 69.555%
Dupont Analysis
Equity Multipler_DuPont
22.40% 1.562% 18.82% 1.512% -- 1.384% 9.48% 1.308%
Net Profit of Parent Company OwnersTo Net Profit_DuPont
4.64% 82.453% 1.32% 81.743% -7.71% 76.675% -5.07% 77.916%
Net Profit To Total Operating Revenue_DuPont
33.49% 23.576% 62.00% 25.560% 55.09% 27.928% 35.45% 14.711%
Net Profit To Total Profit_DuPont
0.29% 83.279% 2.00% 83.826% 0.72% 83.554% -0.72% 82.262%
Total Profit To EBIT_DuPont
-0.30% 99.409% -0.07% 99.840% -0.10% 99.900% -0.96% 99.819%
EBIT To Total Operating Revenue_DuPont
33.51% 28.477% 58.94% 30.541% 54.14% 33.458% 37.74% 17.916%
Currency Unit
CNYCNYCNYCNY

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is a high-tech enterprise that provides comprehensive health management solutions relying on medical laboratory and pathological diagnosis services. Through the business model of providing third-party medical diagnostic services and selling in vitro diagnostic products, the company enables medical technology laboratories such as hospital laboratory, pathology department and central laboratory to help them reduce operating costs and operational risks. improve the quality and technical level of medical services. At present, the company's business covers more than ten provinces and cities, and there are more than ten regional medical laboratory and pathological diagnosis centers, forming a brand, large-scale and standardized laboratory network. The company is an integrated service provider providing overall solutions for the inspection and diagnosis industry, providing third-party medical testing and pathological diagnosis services to medical institutions at all levels, selling in vitro diagnostic products of well-known brands at home and abroad and other professional technical support, in order to meet the differentiated needs of medical institutions at all levels. Medical laboratory and pathological diagnosis services, sales of in vitro diagnosis products, medical diagnosis services, etc. Corporate honors: top 100 Shanghai service enterprises in 2019, top 100 private service enterprises in Shanghai, civilized units in Shanghai, etc.
CEO: --
Market: --
Listing Date: 09/13/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist